Compartilhar
Informação da revista
Vol. 44. Núm. S2.
Páginas S69 (outubro 2022)
Vol. 44. Núm. S2.
Páginas S69 (outubro 2022)
Open Access
FREQUENCY OF BACTEREMIA CAUSED BY EXTENDED SPECTRUM BETALACTAMASE (ESBL)-PRODUCING ENTEROBACTERIA IN FEBRILE NEUTROPENIC PATIENTS WITH A PREVIOUS EPISODE OF ESBL BACTEREMIA
Visitas
1170
M Guaranáa,b, F Santanaa, M Nuccia, SA Nouéra
a Universidade Federal do Rio de Janeiro (UFRJ), Rio de Janeiro, RJ, Brazil
b Universidade Federal do Estado do Rio de Janeiro (UNIRIO), Rio de Janeiro, RJ, Brazil
Este item recebeu

Under a Creative Commons license
Informação do artigo
Suplemento especial
Este artigo faz parte de:
Vol. 44. Núm S2
Mais dados
Objective

Bacteremia caused by ESBL-producing enterobacteria may require treatment with a carbapenem. We evaluated the frequency of bacteremia caused ESBL during febrile neutropenia (FN) in patients with a bacteremia by ESBL documented in a previous episode of FN.

Methods

In this retrospective study we identified all patients with bacteremia by ESBL-producing enterobacteria during an episode of FN and looked at microbiologic documentation infection in subsequent episodes of FN.

Results

From 2001 to 2020 we recorded 1624 episodes of FN occurring in 1045 patients, with 64 episodes of FN with ESBL bacteremia occurring in 40 patients. Fourteen patients had at least another episode of FN after the documentation of ESBL bacteremia (median of 1 episode per patient, range 1 – 8). Four of the 14 patients (28.6%) had ESBL bacteremia in a subsequent episode of FN. The agents of bacteremia were Escherichia coli in 2 patients, and Enterobacter cloacae and Klebsiella pneumoniae (1 each). The time from the first to the second bacteremia by ESBL was 2 months, 7 months, 9 months and 10 months, respectively. One patient had an episode of FN without bacteremia between the two episodes with ESBL. Two patients received meropenem as empiric antibiotic therapy in the second episode and survived. Two patients received cefepime. One switched to piperacillin-tazobactam and survived. The other developed ESBL bacteremia on day 6 of cefepime, switched to meropenem but died on day 10 of meropenem.

Conclusions

Considering that the initiation of inappropriate empiric antibiotic therapy in FN results in poor outcome, and given the high frequency of recurrence (28.6%) of ESBL (and 1 in 4 deaths), patients who develop a subsequent episode of FN should receive empiric antibiotic therapy with activity against the ESBL identified in the previous episode of FN.

O texto completo está disponível em PDF
Baixar PDF
Idiomas
Hematology, Transfusion and Cell Therapy
Opções de artigo
Ferramentas